SEC Filing Summary: Flora Growth Corp. (FLGC)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Flora Growth Corp. (not Zerostack Corp.) on December 17, 2024, covering events occurring on December 15, 2024. The Company is incorporated in Ontario and trades on the NASDAQ Capital Market under the symbol FLGC. It is classified as an emerging growth company.
Key Financial Metrics
This filing is a current report regarding executive compensation and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Compensation Grants
On December 15, 2024, the Company granted equity awards under its 2022 Incentive Compensation Plan to officers, directors, employees, and consultants. All grants vested immediately on the grant date.
- Restricted Stock Awards (RSAs): A total of 1,235,000 RSAs were granted.
- Clifford Starke (CEO): 900,000
- Sammy Dorf (Executive Chairman): 250,000
- Edward Woo (Director): 50,000
- Consultants: 35,000
- Stock Appreciation Rights (SARs): A total of 440,000 SARs were granted with an exercise price of $1.30 and an expiry date of December 15, 2034.
- Dany Vaiman (CFO): 372,500
- Harold Wolkin (Director): 30,000
- Manfred Leventhal (Director): 5,000
- Employees: 32,500
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies were disclosed in this report, other than the standard reference to the full terms of the compensation agreements filed as exhibits.
Investor Verification Checklist
- Verify the dilution impact of 1,675,000 total equity awards (RSAs and SARs) on existing shareholders.
- Review the full text of the Restricted Stock Award Agreement (Exhibit 10.1) and Stock Appreciation Rights Agreement (Exhibit 10.2) for specific forfeiture or performance conditions not detailed in the summary.
- Confirm the current market price of FLGC relative to the $1.30 SAR exercise price to assess immediate intrinsic value.
- Check subsequent filings for any changes to the 2022 Incentive Compensation Plan limits following these grants.